Table 3.

Survival analysis of patients with NSCLC (A), SCC (B), and AC (C). The analyses were performed using Cox proportional hazards model.

A
		Overall Survival
		NSCLC
Univariate				Multivariate
Clinical Feature	p Value	HR	Confidence Interval 95% (HR)	p Value	HR	Confidence Interval 95% (HR)
Age
≤62 vs. >62	0.005911	1.459308	1.114989–1.909957	0.001879	1.540898	1.173239–2.023770
Sex
Female vs. male	0.000262	1.820726	1.319828–2.511725	0.000222	1.845819	1.333147–2.555644
Smoking
No vs. Yes	0.164272	1.325817	0.891007–1.972812
Living in
urban areas
No vs. Yes	0.053255	1.575759	0.993642–2.498906
Clinical stage
I–II vs. III–IV	0.000000	2.351361	1.782315–3.102088	0.009199	1.702469	1.140750–2.540783
Histological grade
G1–G2 vs. G3	0.035460	1.441683	1.025203–2.027353	0.011715	1.564191	1.104626–2.214952
pT
pT1-pT2 vs.
pT3-pT4	0.000000	2.161526	1.639607–2.849582	0.008051	1.559392	1.122639–2.166059
pN
N0 vs. N1–N2	0.000564	1.621062	1.231833–2.133276	0.163298	1.285130	0.903181–1.828603
p63
≤25 vs. >25%	0.097096	0.796109	0.608116–1.042217
TTF-1
≤25 vs. >25%	0.936561	0.989066	0.754490–1.296575
Ki-67
≤25 vs. >25%	0.968136	0.994309	0.751467–1.315628
Cytoplasmic
zyxin levels
in cancer cells
High vs. Low	0.506478	1.095422	0.837153–1.433368
Nuclear
zyxin levels
in cancer cells
Low vs. High	0.649726	1.064851	0.811928–1.396562
B
		Overall Survival
		SCC
Univariate				Multivariate
Clinical Feature	p Value	HR	Confidence Interval 95% (HR)	p Value	HR	Confidence Interval 95% (HR)
Age
≤64 vs. >64	0.083694	1.456415	0.951168–2.230043
Sex
Female vs. male	0.121189	1.595476	0.883699–2.880554
Smoking
No vs. Yes	0.748266	1.159491	0.469650–2.862597
Living in
urban areas
No vs. Yes	0.502217	1.266994	0.634712–2.529139
Clinical stage
I–II vs. III–IV	0.001125	2.128965	1.351164–3.354511	0.247973	1.390731	0.794747–2.433645
Histological grade
G1–G2 vs. G3	0.000091	2.997641	1.729638–5.195220	0.002834	2.414826	1.353633–4.307953
pT
pT1-pT2 vs.
pT3-pT4	0.000534	2.148663	1.393743–3.312486	0.049517	1.682302	1.001099–2.827031
pN
N0 vs. N1–N2	0.908460	1.026365	0.658646–1.599380
p63
≤25 vs. >25%	0.365148	0.767183	0.432303–1.361474
TTF-1
≤25 vs. >25%	0.546339	1.199180	0.664646–2.163608
Ki-67
≤25 vs. >25%	0.836690	0.956480	0.626516–1.460224
Cytoplasmic
zyxin levels
in cancer cells
High vs. Low	0.603775	1.119886	0.730239–1.717444
Nuclear
zyxin levels
in cancer cells
Low vs. High	0.823766	0.953000	0.623872–1.455763
C
		Overall Survival
		AC
Univariate				Multivariate
Clinical Feature	p Value	HR	Confidence Interval 95% (HR)	p Value	HR	Confidence Interval 95% (HR)
Age
≤61 vs. >61	0.439639	1.170082	0.785611–1.742711
Sex
Female vs. male	0.000411	2.195089	1.419128–3.395335	0.000119	2.371420	1.527428–3.681766
Smoking
No vs. Yes	0.331944	1.270446	0.783337–2.060456
Living in
urban areas
No vs. Yes	0.029915	2.244604	1.081842–4.657101	0.029913	2.314151	1.085072–4.935430
Clinical stage
I–II vs. III–IV	0.000000	2.922240	1.945881–4.388492	0.364952	1.311295	0.729573–2.356852
Histological grade
G1–G2 vs. G3	0.880118	1.037945	0.639707–1.684099
pT
pT1-pT2 vs.
pT3-pT4	0.000001	2.846085	1.873553–4.323444	0.002122	2.191669	1.328609–3.615369
pN
N0 vs. N1–N2	0.000000	2.883628	1.922023–4.326332	0.001392	2.317220	1.384130–3.879337
p63
≤25 vs. >25%	0.907950	1.032147	0.603679–1.764726
TTF-1
≤25 vs. >25%	0.133316	0.720412	0.469498–1.105423
Ki-67
≤25 vs. >25%	0.894629	1.033806	0.632080–1.690855
Cytoplasmic
zyxin levels
in cancer cells
High vs. Low	0.758237	1.064633	0.714493–1.586360
Nuclear
zyxin levels
in cancer cells
Low vs. High	0.246701	1.271330	0.846950–1.908353